Novartis investors turn spotlight on M&A after trial setbacks ↧ ↧ Novartis investors turn spotlight on M&A after trial setbacks Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its pipeline.
published
Novartis investors turn spotlight on M&A after trial setbacks ↧
Open the original public source →
Latest documented BWB result
$META market result
I sold the $META $655 Puts 9/25 for $7.60
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.